湖南长沙地区医药产品信息专员

常州千红生化制药股份有限公司

Chinese biochemical pharmaceutical company established on 30 April 2003 at 518 Yunhe Road in the Xinbei district of Changzhou, Jiangsu, and listed on the Shenzhen Stock Exchange small and medium enterprise board on 18 February 2011 under code 002550, with registered capital of about 1.28 billion yuan. Manufactures and trades medicines under its own and contract arrangements and handles pharmaceutical wholesale, retail and import and export, and is a well known Chinese producer of polysaccharide and protease drugs. Its main products cover the pancreatic kininogenase series, heparin sodium and low molecular weight heparin, compound digestive enzyme preparations and the asparaginase series, and it controls subsidiaries including the Jiangsu Zhonghong Bioengineering Drug Research Institute, Changzhou Innoshengkang Biomedical Technology, Changzhou Qianhong Health Technology and Qianhong Biochemical Pharmaceutical (Hubei).